SLS
Sellas Life Sciences Group Inc
12.30$
+7.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.1% | -19.9% | -49.1% | -49.5% | -1.8% | +177.3% | -42.6% | -20.8% | -70.3% | +212.5% | +303.2% | |
| – | +84.7% | -30.1% | -65.1% | -55.4% | +41.2% | +348.0% | -37.6% | -22.9% | -82.1% | +414.7% | +360.7% | |
| – | +25.7% | -39.2% | -87.2% | +130.1% | +36.4% | +385.1% | -39.2% | -20.2% | -85.2% | +448.9% | +417.7% | |
| – | +25.7% | -39.2% | -87.2% | +130.1% | +36.4% | +385.1% | -39.2% | -20.2% | -85.2% | +448.9% | +417.7% | |
| – | +1,080.0% | – | – | – | – | +266.2% | – | – | – | – | – | |
| – | -3,078.5% | – | – | – | – | -18.8% | – | – | – | – | – | |
| – | +17.5% | -40.6% | -100.0% | – | – | +312.9% | -19.3% | +20.9% | – | – | – | |
| – | -2.8% | +0.0% | -67.5% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -50.6% | +0.0% | -20.4% | -51.7% | -32.9% | +0.0% | – | – | – | – | – | |
| – | +58.0% | -45.9% | -15.3% | -62.9% | -9.9% | +72.0% | -66.4% | +164.7% | -11.8% | -29.8% | -25.0% | |
| – | +109.6% | -46.7% | -19.2% | -75.7% | -11.4% | +133.2% | -59.6% | +211.4% | -11.5% | -30.8% | -26.2% | |
| – | +21.2% | +246.0% | -48.9% | – | – | -23.5% | +19.3% | +87.9% | +19.9% | +22.0% | +0.0% | |
| – | -29.7% | -47.4% | +1,291.8% | -67.9% | +3.9% | +19.3% | -54.0% | +56.6% | +68.0% | -37.9% | -15.8% | |
| – | +143.3% | -48.2% | -53.9% | – | – | – | – | – | – | – | – | |
| – | -63.5% | +112.1% | -92.8% | +153.4% | +16.2% | +358.9% | -27.2% | -76.2% | -264.4% | – | +648.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -44.2% | +1,559.8% | -85.9% | +458.8% | +878.3% | +211.8% | +94.1% | +25.3% | +43.2% | +120.3% | +78.2% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.